CYTO vs. CWBR, CYCC, ONCO, RNAZ, AGRX, DRMA, NBY, CNSP, NTBL, and SLRX
Should you be buying Altamira Therapeutics stock or one of its competitors? The main competitors of Altamira Therapeutics include CohBar (CWBR), Cyclacel Pharmaceuticals (CYCC), Onconetix (ONCO), TransCode Therapeutics (RNAZ), Agile Therapeutics (AGRX), Dermata Therapeutics (DRMA), NovaBay Pharmaceuticals (NBY), CNS Pharmaceuticals (CNSP), Notable Labs (NTBL), and Salarius Pharmaceuticals (SLRX). These companies are all part of the "pharmaceutical preparations" industry.
Altamira Therapeutics (NASDAQ:CYTO) and CohBar (NASDAQ:CWBR) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, community ranking, earnings, analyst recommendations, media sentiment, institutional ownership, dividends and valuation.
1.9% of Altamira Therapeutics shares are held by institutional investors. Comparatively, 2.5% of CohBar shares are held by institutional investors. 13.0% of Altamira Therapeutics shares are held by company insiders. Comparatively, 6.5% of CohBar shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Altamira Therapeutics has a beta of 1.79, suggesting that its share price is 79% more volatile than the S&P 500. Comparatively, CohBar has a beta of 1.54, suggesting that its share price is 54% more volatile than the S&P 500.
CohBar received 18 more outperform votes than Altamira Therapeutics when rated by MarketBeat users.
Altamira Therapeutics has higher revenue and earnings than CohBar.
In the previous week, Altamira Therapeutics had 3 more articles in the media than CohBar. MarketBeat recorded 3 mentions for Altamira Therapeutics and 0 mentions for CohBar. Altamira Therapeutics' average media sentiment score of 0.70 beat CohBar's score of 0.00 indicating that Altamira Therapeutics is being referred to more favorably in the media.
Summary
Altamira Therapeutics beats CohBar on 6 of the 8 factors compared between the two stocks.
Get Altamira Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CYTO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CYTO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Altamira Therapeutics Competitors List
Related Companies and Tools
